McKesson Corporation (MCK) Earnings Call Transcript & Summary

August 5, 2026

New York Stock Exchange US Health Care Health Care Providers and Services earnings 56 min

What were the key takeaways from McKesson Corporation's August 5, 2026 earnings call?

In McKesson's first quarter of fiscal 2027, the company reported robust financial results, with revenues increasing by 8% to $105 billion and adjusted earnings per diluted share rising 20% to $9.93, both exceeding expectations. Management raised full-year adjusted EPS guidance to a range of $44.20 to $45.00, up from $43.80 to $44.60, reflecting strong momentum across multiple segments, particularly in North American Pharmaceuticals and Oncology. The results underscore McKesson's operational strength and strategic execution, positioning the company favorably for sustained growth.

What topics did McKesson Corporation cover?

  • Revenue Growth: McKesson's revenues increased by 8% to $105 billion, driven by higher prescription volumes in North American Pharmaceuticals and continued strength in oncology and multispecialty. Management noted, "3 of our reporting segments delivered double-digit operating profit growth, reflecting the strength of our core operating businesses."
  • Adjusted EPS Guidance Raised: Management raised the full-year adjusted EPS guidance to $44.20 to $45.00 from the prior range of $43.80 to $44.60, indicating confidence in the business's performance. Brian Tyler stated, "We're pleased with the strength of our first quarter performance, which gives us the confidence to raise full year adjusted earnings per diluted share guidance."
  • Oncology and Multispecialty Growth: The oncology and multispecialty segment saw a significant revenue increase of 33%, driven by organic growth and contributions from the Core Ventures acquisition. Kenny Cheung highlighted that excluding Core Ventures, revenue growth was approximately 24%.
  • North American Pharmaceuticals Performance: Revenues in North American Pharmaceuticals grew 5% to $86.8 billion, supported by increased prescription volumes, particularly in specialty products. Kenny Cheung mentioned, "Overall 5% growth, really driven by the increased prescription transaction volume, including higher volume from specialty products."
  • Free Cash Flow Concerns: Analysts expressed concerns regarding the declining trend in free cash flow despite rising earnings. Kenny Cheung acknowledged the issue, stating, "First quarter free cash flow is negative because of working capital and inventory timing," but noted improvements compared to the previous year.

What were McKesson Corporation's August 5, 2026 results?

  • Revenue: $105 billion (+8% YoY)
  • Adjusted EPS: $9.93 (+20% YoY)
  • Oncology and Multispecialty Revenue Growth: 33%
  • North American Pharmaceuticals Revenue: $86.8 billion (+5% YoY)
  • Operating Profit: $1.7 billion (+16% YoY)
  • Free Cash Flow: -$372 million

McKesson's strong first quarter results and raised guidance signal positive momentum for the company, driven by robust performance across key segments. However, the declining free cash flow trend raises concerns that investors should monitor closely. Future catalysts include ongoing investments in technology and the successful separation of Medical-Surgical Solutions, while risks may arise from market pricing pressures and regulatory changes.

Earnings Call Speaker Segments

Paula Adkison

executive
#1

Thanks, operator. Good afternoon, everyone, and welcome to the earnings call for McKesson's first quarter of fiscal 2027. With me today are Brian Tyler, who serves as our Chair and Chief Executive Officer, and Kenny Cheung, our Chief Financial Officer. Brian will speak first, Kenny will follow, and after that we'll open things up for questions and answers. During today's discussion, we'll be making forward-looking statements, including forecasts regarding McKesson's operations and results in the future. For more information on risk factors that could cause what actually happens to differ materially from what our forward-looking statements suggest, please see the cautionary statements in today's earnings release and the presentation slides, which are available on our website at investor.mckesson.com, as well as the Risk Factors section in our most recent annual and periodic SEC filings. Details on the non-GAAP financial measures we'll be discussing during this webcast, including a reconciliation of those measures to GAAP results, appear in today's earnings release and presentation slides. A summary of our results for the quarter and our guidance assumptions is also included in the presentation slides. With that, I'll hand things over to Brian.

Brian Tyler

executive
#2

Good afternoon, everyone, and thanks for being with us on today's call. We shared our fiscal first quarter numbers earlier today, and they were robust — showing momentum spread throughout the business and disciplined work by our teams. Revenue climbed 8%, reaching $105 billion, while adjusted earnings per diluted share increased 20% to $9.93. Both figures came in above our own forecasts. During the quarter, three reporting segments achieved operating profit growth in the double digits, reflecting how robust our core operating businesses are. That result is backed by steady, dependable utilization along with gains in volume, and it gets an additional lift from our distinctive solutions portfolio, our concentration, and the way we carry out our strategy. We are pleased with just how solid our first quarter turned out, and that fuels our confidence to lift full year adjusted earnings per diluted share guidance to $44.20 to $45.00, up from the earlier range of $43.80 to $44.60. Before updating everyone on our strategic priority progress this quarter, I want to acknowledge a key leadership change and welcome someone here with me right now: Kenny Cheung, our newly appointed Chief Financial Officer. He came aboard in May, and having him on Team McKesson makes us very enthusiastic. After a rigorous, thorough search process, our confidence is high that Kenny is the correct person to lead McKesson. His deep background spans both finance and operations, with an emphasis on execution and discipline that fits McKesson's operating model well. His background includes steering finance teams at large, intricate companies, and he's shown he can navigate transitions, carry out portfolio plans, and deploy capital toward lasting value. That mix matters a great deal right now, since we're expanding our range of health care services and pushing forward on our strategic portfolio efforts. Equally — perhaps even more — significant is that Kenny believes what we believe: that solid results start with solid teams. He's joining a finance group that already performs at a high level, and I have no doubt he'll strengthen it further while helping steer McKesson into its next stage of growth. Later today, Kenny will share his own views on taking on the CFO position and why he feels good about this business. Let me move on to the quarter now and walk through some important strategic initiatives. These show how we keep making headway on the priorities that are defining McKesson's future. I'll begin with our people and culture, since that's the bedrock of everything we do. We're dedicated to growing strong talent and equipping our teams with the skills they need to keep leading in a world that changes faster and faster. One way we demonstrate that dedication is by giving our teams the tools to lead in an environment shaped by AI. This quarter, we held a day-long enterprise AI training session at our headquarters, where teams came together for lessons and genuine hands-on experience centered on how AI can be applied in practice. Being there personally was a privilege for me, and witnessing the passion and drive throughout Team McKesson was fantastic. Our people continue to make a real impression on me with the way they're advancing, leveraging the technology and AI spending we've committed to, and those initiatives are delivering results you can measure in the business — they're strengthening our operations, our ability to generate fresh concepts, and our capacity to create value over the long term. Now let me turn to the strategic growth pillars, beginning with oncology and the multi-specialty platform. The specialty therapy space continues to grow, representing a substantial market opportunity, and McKesson occupies a remarkably strong spot to capitalize on it. At the base of our oncology and multispecialty strategy are our scaled distribution services — our GPO services, specialty pharmacy, and advanced clinical therapies capabilities — which help providers get the medicines their patients need. Right now, we serve over 14,000 providers spanning a wide variety of community-based specialties. With Unity and OnMark, we assist providers in securing meaningful savings when buying drugs, which makes their practices healthier. Biologics backs commercialization and access for over 200 cancer and other rare disease therapies. And with InspiroGene, we're broadening our advanced therapy capabilities by creating new manufacturer partnerships and delivering complex cell and gene treatments to more patients. All of this together shows how broad our specialty distribution capabilities are as we keep supporting high-quality community-based care. Our specialty distribution capabilities reach across numerous therapeutic areas, yet we are, naturally, especially intent on constructing a differentiated platform for oncology as well as for retina and ophthalmology. Both of these areas have robust innovation pipelines and significant chances for McKesson to provide extra services. In the quarter, our practice management business kept growing. The U.S. Oncology Network expanded to roughly 3,400 providers and cares for over 2 million patients each year; it's a leading force in widening access to care and speeding up innovation in community-based oncology care. PRISM Vision brings together more than 200 providers at 97 sites, which helps expand access to top-notch retina and ophthalmology treatment, again within the community environment. As the ties we have with these providers based in communities deepen, we secure additional chances to expand upon distribution and GPO offerings. This enables us to boost patient involvement in clinical studies, generating additional data and further insights. Sarah Cannon Research Institute, the joint venture we operate for clinical trial services, continues delivering cutting-edge treatments to patients more quickly and closer to their homes. SCRI participated in studies that played a role in 43 of the 52 adult oncology medications cleared by the FDA during 2025. A short while back, SCRI made public a strategic collaboration in oncology research with Pfizer, intended to accelerate the pace of clinical trials. Through this partnership, the two organizations will adopt an advanced model for delivering trials, designed to make trial operations more efficient, improve how well sites perform, and reduce the paperwork and administrative load on investigators as well as care teams. Now turning to our biopharma services platform, we continue to make it possible for providers, biopharma companies, pharmacies, and payers to connect with one another. We are advancing initiatives that improve access and affordability, while also helping patients feel more at ease and assured as they move through the process of filling their prescriptions. In July, we began providing support for the CMS Medicare GLP-1 Bridge program. Our integrated solutions are what we use to deliver the operational workflow infrastructure — for instance, figuring out eligibility, connecting electronic prior authorizations, and handling pharmacy claims transactions for people in Medicare. Once a prior authorization request reaches the payer, a determination comes back in under 30 minutes for 95% of them. That really illustrates the power of our scaled network and how essential our technology is in enabling providers, pharmacies, payers, and biopharma partners to exchange information more efficiently, which means patients can begin therapy sooner. Outside of the CMS program, we continued to see growth in new program wins during the quarter, showing demand is broad across the portfolio. That growth stays diversified across both access and affordability solutions, with brands spanning a wide range of therapeutic categories. One thing that sets our biopharma services offerings apart is how we lean on technology and automation to cut down on hands-on work and boost efficiency. As AI keeps getting better, we're putting those tools to use in the way we create and roll out technology. This quarter, our people took a production-ready external data connection all the way from design through development, testing, and deployment inside one business day — a job that in the past would have stretched across multiple weeks, or possibly months. The effect goes past quicker software building. That added speed lets us answer customer needs faster and get new capabilities into the market earlier.

Brian Tyler

executive
#3

We're still in the early days when it comes to development that's enabled by AI, but cases such as this one show how these capabilities could be extended to a wider scale throughout the segment. Moving to distribution in North America: during Q1, we achieved robust growth in our primary distribution operation, underpinned by steady business fundamentals. Through our scaled distribution capabilities, outstanding service and reach across a variety of channels, we keep providing significant value to those we serve. Independent community pharmacies are one customer channel we've been proud to support for many years. Back in June, we hosted ideaShare, our annual conference. We brought together independent pharmacy leaders from across the nation to learn, to work together, and to explore hands-on answers that help them steer through a health care environment that keeps changing. This year's gathering centered on innovation, which included deploying AI-enabled tools as well as advocacy efforts supporting community pharmacy's long-term strength. It's these kinds of capabilities and connections that boost what our distribution platform offers and help our customers keep caring for patients where they live. In addition, we broke ground on a new regional distribution center located in Moore, Oklahoma — a crucial investment designed to strengthen the resilience and capacity of our pharmaceutical distribution network. Relative to the site we had before, this facility is set to lift throughput by 75%, and that's supported by sophisticated automation, logistics powered by digital tools, and broader cold chain capacity. Through this spending, we're strengthening the backbone of our supply chain and positioning ourselves to support customers at a larger scale, with more resilience and precision. Let me now share a quick status report on what we're doing across our portfolio. Over the quarter, we continued to make good progress carrying out the separation of Medical-Surgical Solutions that we had planned, which allows us to sustain our momentum toward operating as a stand-alone company; in addition, we completed the strategic minority investment from Apollo Funds that we had announced earlier, which brings in an important partner offering capital as well as know-how in handling complicated separations. Beyond that, we completed a $2.25 billion senior secured Term Loan B, which takes us another step toward giving the business its own capital structure, one aimed squarely at driving the greatest possible long-term value for shareholders. I'm pleased to announce today that the McKesson Medical-Surgical business will take on the name Wellverse. Through Wellverse, we're building a future in which both health care providers and patients can thrive. This represents a significant milestone as we create a separate market identity and brand, one that captures what the organization stands for and where it's headed. The MedSurg business is slated to begin officially operating under the Wellverse name in January 2027, with the change rolling out in stages. When you put all of this together, the steps we've taken and the progress toward being ready to separate give Wellverse more room to maneuver financially, and they sharpen our commitment to getting the most long-term worth for shareholders as we carry out the separation we've planned. That's where I'll end my remarks. Momentum kept building across the whole company during the first quarter, and that strengthens how confident we feel about our strategy and about how well our operating model can hold up. Throughout every part of the business, our teams keep executing in a disciplined way, moving our strategic priorities forward and generating ongoing value for customers, partners and shareholders. Things on the policy side keep shifting. McKesson remains heavily engaged, watching closely how significant community-based care is, as well as access, cost and transparency. Not long ago, we were happy to put our name down as a signatory to technology pledges tied to the CMS Healthcare Technology Ecosystem initiative — which I see as a solid illustration of how we keep showing up. As a diversified health care services company, our attention goes toward making the pharmaceutical supply chain more resilient, boosting access and affordability, opening the door for innovation and helping patients get better outcomes. Our strategic focus and our differentiated market position give us confidence that we'll stay well placed for sustained long-term growth. So with that, Kenny, I'll hand things over to you.

Kenny Cheung

executive
#4

Thanks, Brian, and hello to everyone this afternoon. It's a pleasure to be here on my very first earnings call since becoming part of Team McKesson. From the moment I came aboard in May, I've devoted a great deal of time to traveling throughout the organization and out in the field, learning how our business operates and what part we play in moving health care forward. The thing that drew me to McKesson was the distinctive set of capabilities it holds across the health care ecosystem. Watching those capabilities in action with my own eyes has deepened my appreciation for this company, for our employees, and for the significant difference we create daily. This business possesses remarkable scale, executes strongly, and has demonstrated it can consistently produce results. Our robust performance in the first quarter made the strength of the business clear, powered by ongoing momentum throughout the enterprise. Before getting into those first quarter results, let me take a moment to explain how I view my job as CFO. My priorities are straightforward: stay tightly plugged into the business, grasp what drives performance, back disciplined execution, and keep up what I refer to as a strong say-do ratio — you follow through on your commitments. Just as important is putting capital to work wisely and responsibly in ways that generate long-term value for shareholders while pushing our strategic priorities ahead. Those priorities fit with McKesson's long-established operating model and its disciplined capital allocation framework. McKesson has compiled a solid record of investing to fuel growth, preserving financial flexibility, and giving capital back to shareholders. I'm eager to build on that base as we keep carrying out our strategy and generating shareholder value. Now, on to how we performed in the first quarter. We turned in a robust first quarter, with growth spearheaded by North American Pharmaceutical and oncology and multispecialty, plus dependable execution in Prescription Technology Solutions. What we achieved shows how strong the underlying fundamentals are throughout the business, our ongoing operational excellence, and the advantages of our diversified portfolio. Except where I note otherwise, everything I say today relates to our adjusted results. Revenue climbed 8% to reach $105.4 billion, which mirrors solid performance throughout the business. The growth came from greater prescription volumes in North American Pharmaceutical along with sustained strength in oncology and multispecialty. That was partly counterbalanced by anticipated market dynamics, such as reduced branded pharmaceutical pricing after wholesale acquisition cost reductions in January 2026, plus conversions from branded to generic. Gross profit reached $3.7 billion, up 13%, fueled by expansion in North American Pharmaceutical and Oncology and Multispecialty. Those gains mirror higher prescription volumes and strength in specialty, oncology included, together with the upside from branded to generic conversions, which collectively drove gross profit growth throughout the portfolio. Operating expenses rose 10% to $2.1 billion, which mirrors investments in operating expenses made to support growth throughout the business. As we keep investing in the business, we stay disciplined about how we deploy capital, concentrating on investments that produce strong returns, improve our capacity to serve customers, and fuel sustainable growth. During the quarter, we kept generating operating leverage through robust gross profit growth and efficient expense management. For the quarter, operating costs relative to gross profit came in about 150 basis points better than the same period last year, extending the favorable leverage pattern we've been showing. Operating profit reached $1.7 billion, up 16%, fueled by gains in North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions. Those 3 segments each posted double-digit growth in operating profit, which speaks to widespread momentum throughout our core operating businesses. Interest expense came to $75 million, tied to recent financing actions backing the Medical-Surgical Solutions separation, among them the $1 billion secured Term Loan A along with the $2.25 billion secured Term Loan B. We likewise closed a $1 billion revolving credit facility to support the separation, and it stayed undrawn through the quarter. The effective tax rate for the first quarter landed at 21.5%, versus 21.4% a year earlier. Keep in mind that our effective tax rate may move from one quarter to the next, depending on timing and the size of discrete tax items. Diluted weighted average shares totaled 119.2 million, down 5%. Over the quarter, we bought back $2.5 billion of shares, which included $2.25 billion via an accelerated share repurchase program at an initial average price of roughly $755 per share. Adjusted earnings per share rose 20% to $9.93, driven by robust operational results led by North American Pharmaceutical plus the advantage of a smaller share count stemming from share repurchase activity; I'll now move to our segment results, beginning with North American Pharmaceuticals. Revenues totaled $86.8 billion, up 5%, powered by widespread growth from greater prescription volumes, among them a rise in specialty products; that was partly offset by softer branded pharmaceutical pricing after WAC reductions in January 2026 as well as branded to generic conversions. Although branded pricing decreases weighed on revenue, they carried no meaningful effect on operating profit. As a reminder, revenue from branded pharmaceuticals is based on the WAC of those products and will shift with changes in those prices; that said, our branded pharmaceutical contracts are set up so that we get compensated for the fair value of the service we provide; we keep playing an essential role in the pharmaceutical supply chain, offering a strong value proposition to our manufacturer partners. Drawing on our broad capabilities, we provide value past distribution, such as inventory management, central fill and additional services that help customers throughout the pharmaceutical supply chain. Revenue from GLP-1 medications distribution was $15 billion for the quarter, up roughly $3 billion, or 24%, from the prior year. On a sequential basis, GLP-1 revenues climbed 13%. Segment operating profit grew 19% to $894 million, propelled by growth in specialty distribution, including health systems and strategic accounts, along with the timing of new product launches. The business's fundamentals stay solid, underpinned by steady utilization trends, specialty growth and the strength of our generic sourcing program. Our scaled distribution capabilities, including McKesson Plasma and Biologics, leave us well positioned to back growth in specialty distribution volumes. ClarusONE, our generic sourcing program, keeps delivering meaningful value to customers while helping maintain stability of supply. Now on to oncology and multispecialty. Our top line rose 33%, reaching $14.2 billion, with gains coming from throughout the platform, such as organic expansion plus new business wins in provider solutions. Results for the first quarter additionally included what Core Ventures brought in; that acquisition closed on June 2, 2025. If you set aside the Core Ventures contribution, revenue was up about 24%. Operating profit climbed 41% to $405 million, again excluding what Core Ventures added. That operating profit figure rose roughly 15%, propelled by greater specialty distribution volumes, organic and new growth within provider solutions, and expansion across differentiated offerings. Growth remains evident, backed by healthy utilization patterns in the community setting along with steady same-store patient visit increases throughout the provider network. Over in Prescription Technology Solutions, revenue was up 9% to $1.6 billion, fueled by more prescriptions flowing through third-party logistics and access solutions. Operating profit rose 13% to $303 million, lifted by stronger appetite for access solutions, prior authorization services among them. Demand proved robust throughout our technology solutions, with expansion coming from GLP-1 medications as well as other therapeutic categories. Manufacturers keep relying on our solutions to link patients with therapy and to steer through a landscape that grows more complicated by the day. Having such a wide technology and service portfolio means we are well positioned to expand the business while bringing value to customers and patients. Now let's move to Medical-Surgical Solutions.

Kenny Cheung

executive
#5

Revenue came in at $2.8 billion, up 4% from the same period a year earlier, which reflects better growth momentum than we saw in earlier quarters, and that was powered by gains across alternative care settings, with specialty pharmaceutical volume growth leading the way. Operating profit fell 20%, landing at $195 million, and the drivers there were product mix along with a onetime administrative charge, though those were partly offset by what the extended care channel contributed. On June 1, we closed the deal with Apollo Funds that we had announced previously; Apollo Funds now holds a minority stake of roughly 13% in MedSurg. We kept majority ownership and still consolidate that business for financial reporting. In connection with that deal, we booked a noncash, GAAP-only accounting adjustment of $293 million tied to remeasuring the redeemable noncontrolling interest. Finishing up with corporate, corporate expenses totaled $144 million, a 4% increase, mostly because of investments in technology infrastructure. Now let me move to cash and capital deployment. We closed the quarter holding $5.2 billion in cash and cash equivalents, with total liquidity of about $10 billion, comfortably above the minimum threshold. Free cash flow was negative $372 million, which includes $152 million of capital expenditures, as we keep investing in distribution technology, infrastructure and operational capabilities throughout the business. Free cash flow showed a meaningful improvement versus the prior year, thanks to efficient execution on working capital. If you look at the last twelve months, free cash flow remained robust, coming in at about $6.1 billion. That gives us room to put money back into the business and also return capital to shareholders. Over the quarter, we gave back $2.6 billion to shareholders through a mix of buybacks and dividends. In July, our Board of Directors signed off on a 15% increase to the quarterly dividend, which makes 10 straight years of increases. We remain dedicated to growing the dividend in step with our long-term earnings growth target. Turning to our fiscal '27 outlook: first quarter results beat our expectations and made us more confident in the underlying fundamentals of the business. As a result, we're raising our fiscal '27 adjusted earnings per share guidance to a range of $44.20 to $45.00. That stronger full-year projection reflects how solid and dynamic our business is, the results we've already achieved, and our assurance about delivering throughout the year. This works out to adjusted EPS growth between 13% and 15%, once you set aside the Norway divestiture's effect and the gain from selling an equity investment in the U.S. Oncology Network. For fiscal '26, our guidance points to adjusted EPS growth of 15% to 17%, which exceeds our long-term target range of 13% to 16%; looking at fiscal '27, we anticipate revenue growth of 5% to 9% along with operating profit growth of 9% to 13%. I'll expand a bit on what we're seeing for the segments. For North American Pharmaceutical, we're looking at revenue increasing somewhere between 4% and 8%, with operating profit growth landing at the top portion of the earlier 5.5% to 9.5% range. That revised view is a reflection of robust results and healthy basic drivers, such as consistent utilization patterns and momentum in specialty. On top of that, it takes into account quicker spending across the organization during the final half of fiscal '27; we anticipate GLP-1 drugs will keep expanding over the course of fiscal '27, even if the timing moves around between quarters. Turning now to oncology and multispecialty. We're still expecting revenue to grow 14.5% to 18.5%, while operating profit goes up 13.5% to 17.5%. This guidance captures the momentum seen throughout the segment and the worth of our deeply distinctive platform. Inside this segment, distribution along with GPO-linked services continue to make up the biggest share of revenue. As Brian mentioned, we believe expansion within the platform will generate extra value throughout our company. As we keep bringing on additional providers and deepening current ties, that will fuel growth in our practice management services, GPO offerings, data and analytics, plus clinical research support. Such services are built to assist providers and biopharma clients at many points of care and open up further possibilities as time goes on. Just a note, for the fiscal second quarter specifically, we will be up against last year's gains of $51 million in this segment tied to selling an equity investment inside the U.S. Oncology Network. Over in Prescription Technology Solutions, we expect revenue to rise 2.5% to 6.5% and operating profit to grow 11% to 15%. Results in this business don't always move in a straight line. They can swing from quarter to quarter because of a number of drivers, such as utilization patterns, when products launch, and how program support needs change across a product's life cycle; we look for growth in our access and affordability offerings, buoyed by demand spanning both GLP-1 drugs and other therapeutic areas. We also anticipate contributions from new brands and programs being brought on board across the year. The clarity we have on these possibilities, combined with the strength of our current programs and client relationships, underpins what we expect for this segment. Shifting next to the MedSurg segment. We look for revenue to grow 1% to 6% and operating profit to grow flat to 4%. MedSurg carries a varied portfolio and reaches a wide range of customers across alternative care sites, such as ambulatory and extended care, consumer health, and at-home care environments. Rigorous execution and operating efficiencies remain the team's focus, and that strengthens our position while supporting what we're able to deliver for customers; on the corporate line, our expense outlook sits at $580 million to $640 million. Just a reminder, our exit from Norway wrapped up in January. The Norway business contributed $74 million of operating profit during fiscal '26, and $25 million of that came in the fiscal second quarter. Now moving to items below the line; we're looking for interest expense to come in at $380 million to $420 million, which reflects the financing moves we made related to the MedSurg separation. Income attributable to noncontrolling interest should be $295 million to $325 million, which captures the minority ownership stake in MedSurg. We also look for a full year effective tax rate of 18% to 19%, a modest bump from the earlier guidance range, caused by added tax expenses stemming from stronger operating profit growth. When it comes to the tax rate, we'd anticipate the quarterly pattern to look largely like what we saw in fiscal '26, with fluctuations stemming from when discrete tax items land. That brings our outlook to a close on cash flow and capital deployment. There's no change to how we're prioritizing capital allocation. Our focus stays on putting money into our strategic priorities, keeping financial flexibility, giving capital back to shareholders and preserving our investment-grade balance sheet. We're looking at free cash flow in the neighborhood of $4.5 billion to $4.9 billion. During fiscal '27, we expect to buy back roughly $5 billion in shares, and $2.5 billion of that was already done in the first quarter. That activity shows us putting to work the proceeds from the MedSurg financing transaction as well as the Apollo minority investments. Because of this, we project weighted average diluted shares outstanding will land somewhere between 115.5 million and 117.5 million. To wrap up, the strong first quarter results have me pleased, and I feel confident about what's ahead. McKesson stands on solid ground, enjoying promising expansion prospects, a healthy financial footing, and a lengthy history of delivering results. I'm thrilled to play a part as we extend what's already been established and generate value over the long haul. Thanks to all of you for being here today.

Kenny Cheung

executive
#6

I'm eager to connect with lots of you over the coming months, and that includes meeting up at investor events in September. So with that said, let's shift over to the Q&A portion.

George Hill

analyst
#7

So Kenny, I wanted to ask about how the North American Pharma unit did better than expected this quarter — I think you brought up investments. Could you expand on what's behind the organic growth and the margin improvement? It feels like it's been some time since we saw revenue growth that was roughly in line while operating earnings for that segment climbed that sharply. Any one-time risks sitting in there? And any additional detail on that segment would be great.

Kenny Cheung

executive
#8

George, this is Kenny. Sure, happy to. North American Pharmaceutical delivered a very solid quarter for us. I'll cover the top line first, then go through the AOP and margin side. Top line: 5% growth overall, mainly from more prescription transaction volume, which includes greater volume out of specialty products. That got partly offset by reduced branded pharmaceutical pricing after the WAC decrease, which I referenced in the prepared remarks, plus some branded to generic conversion too. Once again, although branded pricing declines weighed on revenue, the effect on operating profit was extremely minimal. For AOP, we were up 19% in the first quarter. The main drivers were distribution of specialty products into the health system and the timing of new product launches. On timing, it came from both the new branded side and branded to generic; those are the 2 factors behind that timing point. On margin, you're right. AOP rose more quickly than revenue, which implies a higher margin mix profile. Broadly, George, in our business, operating margin shifts within the segment can come from a few areas. First is customers, correct? It might be a split among national account, grocery segment, community pharmacy; product can affect the margin profile too, branded specialty, generics, biosimilars, and then clearly channel, right, across retail, specialty and hospitals. So all in all, the business is robust, and we still expect momentum to carry into the outer quarters as well.

Stephen Baxter

analyst
#9

To build on what we discussed regarding North America — when we examine how the guidance was raised, at least relative to what our model shows, it appears the uplift comes mostly from the better-than-expected results in Q1. So I'm curious whether there's anything worth highlighting about what drove that outperformance — whether it might be tied to timing, or perhaps you're simply being cautious about the remainder of the year when considering whether that can be repeated.

Kenny Cheung

executive
#10

Sure, absolutely. You've got that right. At this point, regarding the upward revision for the entire year, the bulk of what's behind it comes from the NAP business — North America Pharmaceutical sitting at the top end of the AOP range of 9.5%. And I believe what's really being asked is about how much confidence sits behind that guidance; so allow me to walk you through my perspective on it. The ongoing momentum in our business makes us happy, and that's exactly why we lifted guidance by $0.40 relative to the prior midpoint. You can observe growth across the board, correct? NAP, which you referenced, has clearly demonstrated momentum, yet it wasn't only NAP — O&M was there too, along with RxTS, and every one of them posted double-digit growth for the quarter. From where I sit, the forecast and the guidance represent, I'd say, what's visible to us today; the intent is a balanced outlook for the year, not a best case scenario. We feel genuinely good about the momentum showing up in the business, the quality of execution in our Q1 results, and the exit rate too. June stood out as the strongest month within the quarter. Naturally, opportunities and risk will always arise along the way. As a management team, we're sharply focused on 3 things; first, carry out with discipline; second, reduce potential risk wherever possible; and finally, put the business in position to seize opportunities as they appear. So as you can tell, it's a very deliberate process. And ultimately, that's why we hold strong confidence in our full year guidance.

Elizabeth Anderson

analyst
#11

When we consider what’s fueling oncology and multispecialty, clearly there was some really, really strong expansion this quarter. How do you view that — might you break it down a bit further? Is Florida Cancer performing about as you expected, or is it surpassing that? And is there anything more you can share to discuss that faster growth within that — in that segment?

Kenny Cheung

executive
#12

Yes. Absolutely. For oncology and multispecialty, we also had an exceptionally strong quarter. Let me break your question down a little. For the quarter, top line revenue grew approximately 33%. Three main factors explain that 33% increase for oncology and multispecialty. First, we experienced very solid expansion in existing provider solutions and specialty distribution; that’s what I refer to as penetration. Second, we also secured new business, and the pipeline remains robust. Last but not least, regarding your final point, there was a contribution from the acquisition side, specifically Core Ventures. If you adjust for Core Ventures out of the 33%, it comes to about 24%. And on the AOP side, we grew 41% year-over-year. If you adjust for Core Ventures, it was approximately 50%, which aligns with the long-term targets.

Brian Tyler

executive
#13

When you look at Florida Cancer in particular, the team's efforts to bring them into McKesson have left us quite satisfied. The operations have been extremely solid. Execution has been fantastic. And we're at the upper end of the guidance range we gave you when the acquisition happened; so it has worked out very well, across cultural integration, operational execution, and financial performance. I'd point out that this quarter marks when we started lapping that transaction.

Brian Tanquilut

analyst
#14

Nice work on the quarter. So, thinking about what you said regarding GLPs, you expect growth to keep going all year. I'm just wondering what you're observing on the market dynamics side, particularly around employer coverage, how you see that playing out down the road, and how that squares with the consumer angle, meaning the direct-to-consumer side of GLPs.

Brian Tyler

executive
#15

Absolutely. So, GLP-1s are still growing in a way that makes us happy. There's a strong cash-pay market for GLP-1s; among all the product categories out there, this is one of the few where I'd say that holds true. That said, the covered segment has also grown very strongly, which you can see in how CoverMyMeds has performed and in the revenue coming through in APD. Coverage has been a topic of some argument, but it hasn't actually shifted all that much, and clearly you can follow this category's overall growth and results and observe that the growth is still healthy and robust.

Lisa Gill

analyst
#16

Brian, you said you're still keeping an eye on policy developments. There are really 2 things I'd like to get clarity on. First, we've been hearing about certain step-by-step modifications related to 340B, and I'm wondering whether that touches your North American business at all. Second, what else has your attention? You and I have previously discussed GLOBE, and how that pricing moves through the physician practice without genuinely affecting things. That said, is there anything beyond that which we ought to be considering on the business side?

Brian Tyler

executive
#17

Absolutely. I'll begin with 340B, though I want to set some context first — everyone should keep in mind this is likely quite early-stage, since the proposal currently on the table is still going through its comment and review phase. Our view is that it matters to allow that process to run its course prior to reaching any judgments regarding the eventual shape, the schedule, or anything of that nature. Lisa, as you're well aware, numerous 340B proposals have surfaced and disappeared across the past half a decade or longer. The 340B landscape is an intricate one. My sense is that whatever reform emerges will generate upsides as well as difficulties for different sets of stakeholders. Certain players stand to gain from clearer operations and greater transparency. Others might see consequences for their economics, their cash flows, and so forth. We work with a large number of those stakeholders — hospitals, health systems, contract pharmacies, community providers, biopharma manufacturers. Because of that, we examine this through a very holistic lens, or several lenses at once. Our aim is going to be assisting our customers in steering through this shift, just as we do with every policy we've needed to handle throughout my 30-year career, and we'll take into account all the constituents we serve as we go about that; moreover, whatever final path this reform follows, we believe our scale, our technology expertise, our compliance expertise and our strong relationships will let us keep generating value. So speculating about the financial impact would be premature. Even so, I have a great deal of confidence in what McKesson can do alongside our customers to steer through it. On your second question, I believe it was more about what other items have our attention. There's clearly plenty of conversation regarding IRA Part D. Let me just note for everyone that it won't take effect until January of 2028; and once more, many things remain unknown. The MFP is something we don't know. Whether reimbursement changes will accompany it is something we don't know. Whether biosimilars will enter the market and as a result remove the eligibility for that program is something we don't know. What's certain to us is that at its core, the community provider setting represents the lowest-cost setting, offering the greatest and simplest access to care. We think the government and our legislators grasp that. We would submit supporting evidence to the initiative you mentioned, GLOBE, since when they tried to drive prices down under that demonstration project, the way to accomplish it involves a manufacturer-to-CMS rebate, so provider practices themselves aren't affected. In our view, that's a solid answer. It's an answer that works. It furthers the aim of bringing drug prices down, yet it also shields the community-based provider, and as a result, it builds a reason for care to be delivered in the community, where costs are low — meaning it benefits the government and makes access simple for patients.

Kenny Cheung

executive
#18

One more point I want to make — when it comes to IRA, there's plenty of talk about WAC pricing, and I'd like to walk you through my perspective on it. Also, just to remind everyone, with WAC pricing, those movements do affect the top line, since we recognize revenue based on the drug selling price. That said, GP and operating profit aren't as sensitive to these price changes. And as you know, over 95% of our branded drugs operate on a fee-for-service basis, meaning we get paid fair value for what we provide. One proof point I'd point to is last quarter, as I noted in my prepared remarks, we did see decreases in WAC pricing — and even with that dynamic, we still delivered GP growth, margin expansion, and strong operating leverage. So that's yet another proof point that we, as a company, understand how to navigate these dynamics.

Erin Wright

analyst
#19

Regarding the North America distribution segment, I believe you mentioned certain accelerated investments you highlighted. You also addressed your confidence in the guidance quite a bit; however, to be more precise, is there anything worth flagging, or that we ought to keep in mind, when it comes to quarterly cadence as we try to chart the rest of the year for that segment?

Kenny Cheung

executive
#20

Yes. When it comes to quarterly cadence, allow me to walk through the enterprise and provide a little additional detail. First, from a North America perspective, seasonality may be a factor. Looking at earlier years, Q4 will be our largest quarter measured by dollars. Looking at RxTS on a quarterly basis, remember that Q4 is when we conduct our annual verification season. Quarterly cadence may fluctuate because of internal investment patterns, the timing of product launches, general product lifestyle, and possible shifts toward other services as well as termination. On that surge, as of now, we have closed the minority interest investment from Apollo. So please ensure you model quarterly NCI properly with respect to that front. Also, regarding the Norway divestiture, which was completed in January 2026, in terms of its phasing, this quarter, Q2, it was approximately $25 million on a year-on-year basis. And finally, on US Oncology and Multi-Specialty from a quarterly cadence perspective, this quarter, meaning Q2, we have a $51 million gain that we are lapping from last year, driven by the sale of equity investment within the USON business.

Eric Percher

analyst
#21

I'd like to come back to Onco and Multi, and I appreciate what you said about organic growth. There's been quite a bit of conversation about what today's growth rate actually is. What I'd be interested in is your 15%, or how you see it over the long term — in your view, how does the market's growth compare with yours, given the assets and specialties you're in? And then, Brian, maybe I'll turn back to you on how that growth can be extended through bringing on more providers or other services.

Brian Tyler

executive
#22

Yes. Look, we're quite happy with the growth we've been seeing in oncology and multispecialty. Even after adjusting for the FCS impact in the last quarter, this segment grew 24% for us; that reflects a mix of the organic growth that's inherent in the market, same-store visits, or patient traffic, which rose sequentially compared with our prior quarter; we keep building our practices by recruiting physicians and expanding geographically. All of that, Eric, is what underpins the growth algorithm. Our thinking isn't that there will be chances to add another FCS of that scale, but we still believe that expanding geographically and recruiting in order to build the practices locally will matter a great deal to the growth algorithm. And as we keep bringing technologies — AI or others — into how these physicians are supported, that ought to let us increase our capacity to see patients, and that's a growth driver we haven't really discussed much previously. So we're very, very happy with the performance. We feel quite good about where our business stands, the quality of the service we provide and the difference we make in patients' lives.

Kenny Cheung

executive
#23

This guidance, along with the outlook, mirrors how strong the entire business is and how valuable our deeply differentiated platform has proven to be. That 15% growth figure I brought up before is entirely organic — no M&A is baked into it — and going forward, we anticipate it carrying on so we reach the long-term targets. As I said, growth is going to arrive from a few different places, correct? Sure, there will be M&A here and there, some tuck-ins here and there; beyond that, you get more throughput pushed through the provider network we already have, plus new business wins too. On the USON side, as you're likely aware, we count 3,400 providers, yet we also hold a larger basket totaling 14,000, since we back the GPO and distribution side too. So broad-based growth across the board is what we expect.

Kevin Caliendo

analyst
#24

Kenny, glad to have you with us. The enthusiasm on these calls is fantastic. My question is about free cash flow. I realize the guidance is unchanged, but I want to — this is really directed at you, Kenny; it's essentially declining not only compared to last year, but across the past 2 years as well. I understand that with your business, things are always uneven in this manner; yet at this point this is kind of a 2-year pattern, with earnings rising much more quickly than free cash flow. And I'm just curious whether there's something there we ought to be considering, or when we might see free cash flow begin to pick up somewhat, since purely on the surface, it appears slightly irregular or slightly strange that it isn't increasing in line with the income.

Kenny Cheung

executive
#25

Yes. I get the question. I tracked it entirely. So in quarter one, we had — typically free cash flow in quarter one comes in negative owing to working capital and the timing of inventory. That being said, though, this year showed significant improvement. A year ago, we were approximately down $1 billion on free cash flow; in this quarter, it came to approximately $370 million. So a great deal of improvement there. Much of that is structural, which is extremely, extremely heartening. It's still early in the year for us; and as you noted, there are many moving pieces around the day of the close — the week of the close, and so on. So at present, we're providing — we're maintaining the existing guide given during the previous quarterly call. That said, from where I sit, we are witnessing through technology, AI, and so forth, truly structural gains in how we manage working capital; and I do think a portion of that ought to carry through for the remainder of the year. So as we move forward with these projects and additional developments on this front, that's my response. Additional developments on this front. At this moment, I feel quite confident about our forecast. And we do have chances along the way to exceed that throughout the year.

Michael Cherny

analyst
#26

Yeah, and welcome, Kenny. Sorry for returning to this topic, but I was just doing a bit of quick arithmetic, and even if you reach the top end of your North American Pharma guidance for the remaining part of the year, that puts you at roughly 6.8%. That's really right in line with the LRP. But when you consider the moving parts for that segment during the second half, is there anything regarding comp dynamics we should keep in mind? And how do you view the road ahead, in terms of both utilization and possible additional launches in that market? I'd really appreciate it.

Brian Tyler

executive
#27

Yes. Well, once again, we're very happy with the first quarter and the momentum right out of the gate. In our view, the utilization landscape remains stable. What I'd say, Michael, is that we likely saw some favorability in the generics part of the business that arrived earlier in the year than we had anticipated. That clearly will be at the cost of later quarters, since we got the benefit early. Beyond that, I don't believe there's anything structural that — Kenny, perhaps you'd like to add.

Kenny Cheung

executive
#28

Correct — and to build on what I said before, the timing of certain product launches shifted. Those launches, as I noted previously, involved both our new branded items and branded generics, and that did cause a slight bump in Q1 AOP growth. Now, when I look at the remainder of the year with respect to NAP guidance, the revised outlook captures strong results and healthy underlying fundamentals, among them continued steady utilization patterns and growth in specialty. It also accounts for stepped-up business investments during the back half of the year, aimed at growth as well as AI; all of that is included in the forecast we have now; and the ROI is accretive to our enterprise, with the payoff expected most likely to arrive at the start of 2028. Here at McKesson, we constantly consider how to seize the current opportunity while simultaneously preparing for what lies ahead; and doing these things is right for the company.

Brian Tyler

executive
#29

It's always been part of our algorithm.

Kenny Cheung

executive
#30

That's precisely right.

Brian Tyler

executive
#31

All right. So, once more, thanks to each of you for being with us today; your questions are always something we value, and we appreciate Cynthia helping to run the call. The results McKesson posted in quarter one came in strong, and they demonstrate how solid our business is, along with the underlying conditions of the markets where we operate and the distinctive solutions we offer in those markets. I also want to express gratitude to every McKesson employee for their commitment, and for the steadfast dedication they show toward our partners, our customers and their patients. Looking forward, we have confidence in our capacity to keep executing, to build on the momentum of the business and to produce shareholder value over the long term. Many thanks once more to all of you. Enjoy your evening.

Operator

operator
#32

We appreciate everyone being on this conference call today. At this point you're free to hang up, and I hope the rest of your day goes well.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete McKesson Corporation transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to McKesson Corporation earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in McKesson Corporation or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.